Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reached, it would rank among the largest disclosed patent settlements in biopharmaceutical industry history. The post Moderna to Pay Up…
The problem isn’t whether these modalities work, but how they’re being implemented into the workforce. Efficient rollout, proper training, and ongoing education are vital for these new methods to reach their full potential. The post AI, VR, and the Training Gap: Why New Healthcare Tech Fails Without Workforce Readiness appeared first on MedCity News.
The real promise of AI agents lies not in their intelligence but in their ability to deliver empathy at scale. By taking on repetitive tasks and restoring capacity to the people who deliver care, AI can help rebalance the system toward its original, deeply human purpose. The post Actionable AI in Clinical Settings: Trust and…
[Sponsored] Healthcare executives spoke with MedCity News on how their businesses are using AI to shape the clinician and patient experience. The post Capturing the Vibe at ViVE 2026, Healthcare Executives Share Insights on Medication Adherence and Implementing AI [Video] appeared first on MedCity News.
Grow Therapy’s Series D funding was led by TCV and Growth Equity at Goldman Sachs Alternatives, with participation from BCI, Menlo Ventures, Sequoia, SignalFire and Transformation Capital. The post Grow Therapy Raises $150M to Expand Employer, Health System Partnerships appeared first on MedCity News.
Ampreloxetine’s Phase 3 failure in multiple system atrophy is the third disappointing clinical trial outcome for the Theravance Biopharma drug. The biotech will now wind down all R&D and explore options that could include the sale of the company. The post Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D appeared…
Last week, Trump proposed cutting out insurers and giving Americans cash to buy their own healthcare, claiming it would lower costs. Ali Diab, an economist and CEO of Collective Health, said the plan overlooks the real problem: concentrated payer power, opaque pricing and the financial risk people face without insurance. The post Why Trump’s ‘Cash…
For providers, the rules mean more control over monitoring and the chance to keep a larger share of reimbursement. For device companies, they create a chance to show measurable value and guide clinicians through a system that is shifting quickly. The post How New Medicare Rules Will Reshape Cardiac Monitoring and Remote Patient Care appeared…
When healthcare delivery strategies shifted to the home out of necessity during the pandemic, healthcare consumers began to question the value of navigating the old system, one that requires time off work, transportation, childcare, and long waits just to have basic needs met. The post Healthcare At Your Door Is Now The Expectation. There’s No…
[Sponsored] At the ViVE conference in LA, Smarter Technologies Chief Medical Officer Ruben Amarasingham MD talked with Katie Adams about the company’s larger goals for AI: to improve the accuracy of data and make healthcare less burdensome for physicians and clinicians. The post Balancing the Role of Physicians and AI [Video] appeared first on MedCity…